PTCT — Stock Film
STOCK FILMSCENE 1/11PTCT · $78.52
Stock Expert AI presents
PTCT
PTC Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
PTC Therapeutics, Inc. A quick introduction.

On the stock market since 2013, it operates in the world of health and science. It has 991 employees. Now — the numbers.

on the stock market since 2013
991 employees
$6.5B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $39 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 39%

This is an established company with proven profits.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 34% a year over the last 4 years. Red columns mark years that ended in a loss.

$538.6M
2021
$698.8M
2022
$937.8M
2023
$806.8M
2024
$1.7B
2025
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $1.5B would still be left in the vault — a solid cushion for hard times.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
76
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
41
weak

Clearly below the class average.

VALUATION
48
weak

Clearly below the class average.

GROWTH
89
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
71
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Sales are growing fast10/10
Fat profit on each sale10/10
A strong cash pile8/10
WEAK SPOTS
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Trading below its recent peak.

The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.

1
THE BRIGHT SIDE · 1/3
A fat profit margin

The net profit margin is 39% — that slice of every sale is the company’s cushion in hard quarters.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 3 years, sales grew about 35% a year on average.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $1.9B in the vault; even if every debt were paid off, $1.5B would remain.

1
THE RISKS · 1/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 41/100.

2
THE RISKS · 2/3
The price runs ahead of the earnings

Today’s price already includes part of tomorrow’s optimism. Report-card grade: 48/100.

3
THE RISKS · 3/3
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, PTCT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: PTCT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (48/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film